Nafamostat mesylate
Nafamostat mesylate is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target transient receptor potential cation channel subfamily M member 7, acid-sensing ion channel 2, serine protease 1, complement C1r subcomponent, tryptase alpha/beta-1, acid-sensing ion channel 1, and acid-sensing ion channel 3.
Download report
Favorite
COVID-19
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
15 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | — | 1 | 2 | — | 3 |
| Liver transplantation | D016031 | EFO_0010682 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | U07.1 | 1 | 5 | 4 | — | — | 7 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Critical illness | D016638 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics | D010599 | 2 | — | — | — | — | 2 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | NAFAMOSTAT MESYLATE |
| INN | nafamostat |
| Description | Nafamostat is a member of benzoic acids and a member of guanidines. |
| Classification | Small molecule |
| Drug class | enzyme inhibitors: proteolytic enzyme inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CS(=O)(=O)O.CS(=O)(=O)O.N=C(N)Nc1ccc(C(=O)Oc2ccc3cc(C(=N)N)ccc3c2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 81525-10-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3989553 |
| ChEBI ID | — |
| PubChem CID | 4413 |
| DrugBank | DB12598 |
| UNII ID | Y25LQ0H97D (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
TRPM7
TRPM7
ASIC2
ASIC2
PRSS1
PRSS1
C1R
C1R
TPSAB1
TPSAB1
ASIC1
ASIC1
ASIC3
ASIC3
Organism
Homo sapiens
Gene name
TRPM7
Gene synonyms
CHAK1, LTRPC7
NCBI Gene ID
Protein name
transient receptor potential cation channel subfamily M member 7
Protein synonyms
Channel-kinase 1, Long transient receptor potential channel 7, LTRPC ion channel family member 7, LTrpC-7, LTrpC7, transient receptor potential-phospholipase C-interacting kinase
Uniprot ID
Mouse ortholog
Trpm7 (58800)
transient receptor potential cation channel subfamily M member 7 (Q923J1)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,590 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
75,180 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more